You are here

Report: Market for Pancreatic Cancer Therapies Expected to Double to $1.3 Billion Over Next Decade

Growth fueled by three new agents (May 7)

Decision Resources, a research and advisory firm located in Burlington, Mass., finds that the pancreatic cancer therapy market will nearly double to $1.3 billion in 2022, owing to the launch and rapid uptake of three high-priced agents — Abraxane (paclitaxel, Celgene/Taiho); Estybon (rigosertib, Onconova Therapeutics/Baxter International/SymBio Pharmaceuticals); and MM-398 (Merrimack Pharmaceuticals), a novel formulation of irinotecan. Even though these agents do not substantially improve the overall survival of pancreatic cancer patients, they will have a significant effect on current treatment, the company says.

The report also finds that a significant commercial reward awaits developers of therapies that are more effective and better tolerated than the FOLFIRINOX regimen (folic acid [leucovorin calcium], fluorouracil, irinotecan hydrochloride, and oxaliplatin) in this disease, as the need for efficacious, well-tolerated therapies will remain through 2022.

“There is a dire need for novel therapies to, at a minimum, match FOLFIRINOX’s efficacy,” said analyst Orestis Mavroudis-Chocholis, PhD. “FOLFIRINOX is reserved for young, fitter patients, who are better able to tolerate it, and is therefore prescribed only to a minority of pancreatic cancer patients who typically have rapidly progressing disease and declining performance status. Even an agent with equal efficacy but a better safety profile will quickly become the standard of care in pancreatic cancer.”

The report also finds that surveyed physicians are excited by the prospect of stromal over-expression of secreted protein rich in cysteine (SPARC) as a predictive biomarker for a response to Abraxane and hope that this could herald the start of a personalized approach to the treatment of pancreatic cancer.

Source: Decision Resources; May 7, 2013.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy